Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Bilastin

Generic name
Bilastin
Brand name
ATC Code
R06AX29

Pharmacokinetics in children

In a phase II study to investigate the pharmacokinetics, pharmacokinetic data were collected in children who received
10 mg bilastine once daily as a melting tablet (31 children aged 4 to 11 years with allergic rhinoconjunctivitis or chronic urticaria). Pharmacokinetic analysis of plasma concentration data showed that paediatric dosing of 10 mg bilastine once daily resulted in comparable systemic exposure to that observed after a 20 mg dose in adults and adolescents (mean AUC 1014 ng × h/ml in children aged 6 to 11 years). [SmPC Allegra]

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Available formulations

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Dosages

Allergic rhinoconjunctivitis and urticaria
  • Oral
    • 6 years up to 12 years and ≥ 20 kg
      • 10 mg/day in 1 dose
      • Administration 1 hour before or 2 hours after food intake.

    • 12 years up to 18 years
      • 20 mg/day in 1 dose
      • Administration: 1 hour before or 2 hours after food intake.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

Common (1-10%): Rhinitis, headache, allergic conjunctivitis, abdominal pain/pain in the upper abdomen

Occasional (0.1-1 %): Dizziness, loss of consciousness, eye irritation, diarrhoea, nausea, swollen lip, eczema, urticaria, fatigue

[SmPC Allegra®]

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions

No information available on specific warnings and precautions in children.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

References

  1. A. Nattermann & Cie. GmbH (Sanofi), SmPC Allegra (7004523.00.00) , www.fachinfo.de, 12/2022
  2. A. Nattermann & Cie. GmbH (Sanofi), SmPC Allegra (7004523.00.00), www.fachinfo.de, 12/2022

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Changes

Changes